Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)

血清学检测中心以改善大流行性 COVID-19 的结果 (STOP-COVID)

• 批准号: 10222406
• 负责人: Ann Scheck McAlearney
• 金额: $ 395.28万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-18 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10222406
• 关键词: 2019-nCoV; Address; Affect; Antibodies; Antibody Response; Antigens; Applied Research; Archives; Basic Science; Behavioral; Bioinformatics; Biological Assay; Biometry; COVID-19; COVID-19 pandemic; Characteristics; Clinical; Clinical Services; Common Cold; Communicable Diseases; Communication; Communities; Cost Sharing; Data; Data Analyses; Disease; Disease Outcome; Educational workshop; Enzyme-Linked Immunosorbent Assay; Epidemiology; Facility Accesses; Fire - disasters; Fostering; Future; Gene Expression; Genetic; Goals; Health Services; Household; Immune; Immune response; Individual; Infection; Infrastructure; Institutes; Knowledge; Laboratories; Leadership; Longitudinal Studies; Maintenance; Methodology; Molecular; Monoclonal Antibodies; Natural History; Observational Study; Ohio; Outcome; Pathogenesis; Peripheral Blood Mononuclear Cell; Police; Prevalence; Process; Psychometrics; Public Health; Reagent; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Risk; Role; Sampling; Science; Serologic tests; Serological; Serum; Severities; Severity of illness; Test Result; Testing; Translational Research; Translations; United States Dept. of Health and Human Services; Universities; Vaccination; Vaccines; Viral; Virus; Work; biobank; biosafety level 3 facility; cohort; complex data; coronavirus disease; cost; data management; data quality; data sharing; design; first responder; high risk; implementation strategy; improved; improved outcome; innovation; insight; novel; pathogen; population health; respiratory virus; response; stem; synergism; transcriptomics; transmission process; virology; virome; virtual

Overall Project Summary Stemming the spread of COVID-19 will require research that cross-cuts basic, translational, and applied sciences. The Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP- COVID) is proposed as a transdisciplinary entity to understand the interface between exposure risk, transmission, immune responses, disease severity, protection, and barriers to testing/vaccination, with the goal of improving population health and clinical outcomes. The Center will utilize state-of-the-art serological and molecular tests, developed at OSU, in a longitudinal study of first responders, a group at continual high risk of SARS-CoV-2 exposure, as well as their household contacts. Through the proposed work, STOP-COVID investigators will understand critical aspects of: (i) transmission in both asymptomatic and symptomatic individuals, (ii) immune, host, and viral determinants of disease outcome, and (iii) factors associated with immune protection. Center investigators will also identify best practices for communication of test results and information about COVID-19 to improve understanding of risk, transmission, and protection, while reducing access barriers to testing. The Center to STOP-COVID will: Aim 1 Develop Institute Infrastructure through three shared resource cores: 1. An Administrative Core that provides overall direction and leadership, coordinating all Center activities as well as Project–Core–SeroNet interactions; 2. A Testing and Biorepository Core, whose role is to perform first-tier serologic and viral testing during our longitudinal study using high throughput ELISA and neutralization assays developed at OSU, and cost-shared by OSU; and 3. A Data Management and Analysis Core that will provide project investigators with a centralized resource for biostatistics, bioinformatics, epidemiology, and psychometrics expertise. Aim 2: Conduct three innovative research projects to address: Project 1: Parallel serological and viral testing to determine COVID-19 prevalence, transmission, and protection in extended first responder cohorts. This project will also generate serology data for vaccines or mAbs, once available to this presumably high-priority group; Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection. This project will evaluate COVID-19 serological responses in the context of SARS-CoV-2 and common cold CoV (CCCoV) antibodies, using novel assays specific for a panel of antigens. Project 2 also will employ transcriptomics to understand how host genetics, CCCoV, other respiratory viruses, and immune responses contribute to pathogenesis; and Project 3: Responding to changing serological and viral information around COVID-19. This project will incorporate results from Projects 1 & 2 and SeroNet to inform best practices in risk communication, provide behavioral guidance to decrease transmission, and enhance protection from disease. Aim 3: SeroNet Participation and Sharing of Data and Best Practices. We will leverage STOP-COVID infrastructure to share data, results, reagents, and best practices with SeroNet, which will drive new discoveries and their translation into actionable strategies for implementation across all groups affected by COVID-19.

项目总体概要 阻止 COVID-19 的传播需要跨领域的基础、转化和应用研究 改善大流行性 COVID-19 的血清学检测中心 (STOP- COVID）被提议作为一个跨学科实体来理解暴露风险、传播、 免疫反应、疾病严重程度、保护以及检测/疫苗接种的障碍，目标是改善 该中心将利用最先进的血清学和分子检测， 俄勒冈州立大学在对急救人员的一项纵向研究中开发了这项研究，急救人员是一群处于 SARS-CoV-2 持续高风险的群体 通过拟议的工作，STOP-COVID 调查人员将了解他们的接触情况及其家庭接触者。 了解以下关键方面：(i) 在无症状和有症状个体中传播，(ii) 免疫， 宿主和疾病结果的病毒决定因素，以及（iii）与免疫保护中心相关的因素。 研究人员还将确定沟通测试结果和有关 COVID-19 的信息的最佳实践 提高对风险、传播和保护的理解，同时减少检测的准入障碍。 STOP-COVID 中心将： 目标 1 通过三个共享资源开发研究所基础设施 核心： 1. 提供总体指导和领导、协调所有中心活动的行政核心 以及 Project-Core-SeroNet 交互； 2. 测试和生物库核心，其作用是执行 在我们的纵向研究中使用高通量 ELISA 和中和进行一级血清学和病毒检测 3. 数据管理和分析核心，由 OSU 开发，并由 OSU 分摊费用； 为项目研究人员提供生物统计学、生物信息学、流行病学和 目标 2：开展三个创新研究项目，以解决： 项目 1：并行 血清学和病毒检测，首先确定 COVID-19 的流行情况、传播情况和保护措施 一旦可用，该项目还将生成疫苗或单克隆抗体的血清学数据。 可以说是高优先级组；项目 2：COVID-19 严重程度的血清学和分子决定因素 该项目将评估 SARS-CoV-2 背景下的 COVID-19 血清学反应。 和普通感冒冠状病毒 (CCCoV) 抗体，还使用针对一组抗原的新型检测方法项目 2。 将利用转录组学来了解宿主遗传学、CCCoV、其他呼吸道病毒和免疫系统如何 反应有助于发病机制；项目 3：应对不断变化的血清学和病毒信息 该项目将整合项目 1 和 2 以及 SeroNet 的结果，为最佳实践提供信息。 在风险沟通中，提供行为指导以减少传播，并加强防范 目标 3：SeroNet 参与以及数据和最佳实践共享。 与 SeroNet 共享数据、结果、试剂和最佳实践的基础设施，这将推动新的发现 并将其转化为可行的战略，以便在受 COVID-19 影响的所有群体中实施。